Medical Exoskeleton Market Size and Share Analysis by Component (Hardware, Software), Type (Powered, Passive), Extremity (Upper Extremities, Lower Extremities, Full Body) - Global Industry Demand Forecast to 2030
세계의 의료용 외골격(Medical Exoskeleton) 시장은 2023년에 4억 8,580만 달러의 규모에 이르렀고, 2030년에는 44.8%의 CAGR로 추이하며 성장 할 것으로 예상되며, 63억 3,680만 달러에 달할 것으로 예측됩니다.
이 산업의 성장은 주로 신체장애인의 급증, 노인 인구 증가, 정형외과 수술 건수 증가 때문입니다.
세계 시장을 선도하는 북미
북미는 2023년에는 55%의 점유율을 차지해 최대 시장이 되어 향후 몇 년간 크게 전진할 예정입니다. 이는 노인 인구의 급증, 외골격에 대한 정부 지원 증가, 신경 질환의 높은 발병률 등에 근거합니다.
아시아 태평양은 의료에서 자금 조달 증가, 최근 제품 승인, 이동 및 재활 지원이 필요한 환자 증가로 인해 가장 빠른 속도로 발전하고 있습니다.
부문별 분석
컴포넌트별로는 하드웨어 카테고리가 2023년에는 60%의 점유율로 업계를 선도해 향후 수년간 45.0%의 CAGR로 성장할 예정입니다. 이는 외골격이 동력 시스템, 센서, 제어 시스템, 액추에이터 등과 같은 다른 하드웨어를 사용하여 제조되기 때문입니다.
유형별로는 최근의 개량에 의해 동력식이 점유율이 큽니다.
사지별로는 2023년에는 하지외골격이 리드했습니다. 이는 발목, 발, 무릎 관절 및 고관절을 포함한 하반신 부위의 장애의 유병률 증가로 인한 것으로 예상됩니다.
세계의 의료용 외골격 시장에 대해 분석했으며, 시장의 기본 구조/최신 정세/주요 촉진·억제 요인/세계 전체 및 지역별·주요 국가 시장 규모 동향 전망(금액 기준, 2017-2030년)/구분별 상세 동향/현재 시장 경쟁 구도/주요 기업 프로파일 등 정보를 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 산업 전망
- 시장 역학
- 동향
- 성장 촉진 요인
- 억제 요인/과제
- 성장 촉진 요인/억제 요인의 영향 분석
- COVID-19의 영향
- Porter's Five Forces 분석
제6장 시장
- 개요
- 시장 매출 : 컴포넌트별(2017-2030년)
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 사지별(2017-2030년)
- 시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
- 개요
- 시장 매출 : 컴포넌트별(2017-2030년)
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 사지별(2017-2030년)
- 시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아 태평양 시장
제10장 남미 시장
제11장 중동 및 아프리카(MEA) 시장
제12장 미국 시장
- 개요
- 시장 매출 : 컴포넌트별(2017-2030년)
- 시장 매출 : 유형별(2017-2030년)
- 시장 매출 : 사지별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
- 시장 진출기업 및 제공 제품 및 서비스 목록
- 주요 기업의 경쟁 벤치마킹
- 주요 기업의 제품 벤치마킹
- 최근의 전략 전개 상황
제30장 기업 프로파일
- Ekso Bionics Holdings Inc.
- ReWalk Robotics Ltd.
- Parker-Hannifin Corporation
- BIONIK Laboratories Corp.
- Rex Bionics Ltd.
- B-Temia Inc.
- Bioventus LLC
- Hocoma AG
제31장 부록
LYJ
The medical exoskeleton market generated a value of USD 485.8 million in 2023, which will increase to USD 6,336.8 million, with a 44.8% CAGR, by 2030.
The growth of this industry is mainly because of the surging count of people with physical disabilities, the increasing elderly population, and the rising number of orthopedic surgeries.
For instance, as per the World Health Organization, an estimated 1.3 billion individuals, or 1 out of 6 people globally, experience significant disability.
Moreover, as per the United Nations, the number of people who are 65 years and above is rising at a faster rate compared to those below this age. Also, the percentage of the worldwide population aged 65 and above is likely to reach 16% in 2050 from 10% in 2022.
Furthermore, more than 300 million orthopedic operations are performed across the globe every year, 75% of which take place in developed nations.
In addition, the surging number of road accidents, strokes, and severe injuries, is also aiding the expansion of this industry. The WHO says that around 1.3 million people die annually because of road traffic crashes. Therefore, the rising acceptance of medical exoskeletons for the curing of injuries is boosting industry expansion.
North America Leading the Global Market
North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the coming years. This is because of the surging elderly population, rising government support for exoskeletons, and high incidence of neurological ailments.
For example, Human in Motion Robotics Inc. (HMR), in September 2022, declared a CAD 663,000 contract from Innovative Solutions Canada for the Department of National Defence Canada.
The contract is for the Canadian government to buy HMR's next-generation lower-extremity exoskeleton, XoMotion, which is intended to remove people's reliance on wheelchairs and enable them total mobility.
APAC is advancing at the fastest rate, owing to the increasing funding in healthcare, recent product approvals, and a growing patient pool requiring mobility and rehabilitation support.
Segmentation Analysis
The hardware category, based on component, led the industry in 2023, with a 60% share, and it will propel at a 45.0% CAGR in the coming years. This can be because exoskeletons are produced using different pieces of hardware, such as powered systems, sensors, control systems, and actuators.
The powered category, based on type, was the larger contributor to the industry, owing to the recent improvements in them. For example, Stanford University, with investment from the NIH, has developed an exoskeleton that rapidly adapts to users' movement while they walk normally.
Additionally, major players in this industry are concentrating on incorporating cutting-edge technologies like AI, to improve their product performance. AI increases the human potential, along with the efficiency of the devices.
In 2023, lower-extremity exoskeletons led the extremity category. This can be credited to the increasing prevalence of lower body parts disability, including the ankles, feet, and knee & hip joints.
Competitive Landscape
Businesses are concentrating on partnerships & acquisitions:
In November 2021, Ottobock declared the acquisition of 100% shares of suitX, a U.S.-based business spun out of the Robotics & Human Engineering Lab at the University of California, which is mostly involved in medical exoskeletons R&D.
In April 2022, Blackrock Neurotech declared that it will partner for R&D with Phantom Neuro for its patent-pending Phantom X system.
With the rising number of people with physical disabilities across the globe, the medical exoskeleton industry will continue to grow in the coming years.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by component
- 1.4.2. Market size breakdown, by type
- 1.4.3. Market size breakdown, by extremity
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Component (2017-2030)
- 6.3. Market Revenue, by Type (2017-2030)
- 6.4. Market Revenue, by Extremity (2017-2030)
- 6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Component (2017-2030)
- 7.3. Market Revenue, by Type (2017-2030)
- 7.4. Market Revenue, by Extremity (2017-2030)
- 7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Component (2017-2030)
- 8.3. Market Revenue, by Type (2017-2030)
- 8.4. Market Revenue, by Extremity (2017-2030)
- 8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Component (2017-2030)
- 9.3. Market Revenue, by Type (2017-2030)
- 9.4. Market Revenue, by Extremity (2017-2030)
- 9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Component (2017-2030)
- 10.3. Market Revenue, by Type (2017-2030)
- 10.4. Market Revenue, by Extremity (2017-2030)
- 10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Component (2017-2030)
- 11.3. Market Revenue, by Type (2017-2030)
- 11.4. Market Revenue, by Extremity (2017-2030)
- 11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Component (2017-2030)
- 12.3. Market Revenue, by Type (2017-2030)
- 12.4. Market Revenue, by Extremity (2017-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Component (2017-2030)
- 13.3. Market Revenue, by Type (2017-2030)
- 13.4. Market Revenue, by Extremity (2017-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Component (2017-2030)
- 14.3. Market Revenue, by Type (2017-2030)
- 14.4. Market Revenue, by Extremity (2017-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Component (2017-2030)
- 15.3. Market Revenue, by Type (2017-2030)
- 15.4. Market Revenue, by Extremity (2017-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Component (2017-2030)
- 16.3. Market Revenue, by Type (2017-2030)
- 16.4. Market Revenue, by Extremity (2017-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Component (2017-2030)
- 17.3. Market Revenue, by Type (2017-2030)
- 17.4. Market Revenue, by Extremity (2017-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Component (2017-2030)
- 18.3. Market Revenue, by Type (2017-2030)
- 18.4. Market Revenue, by Extremity (2017-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Component (2017-2030)
- 19.3. Market Revenue, by Type (2017-2030)
- 19.4. Market Revenue, by Extremity (2017-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Component (2017-2030)
- 20.3. Market Revenue, by Type (2017-2030)
- 20.4. Market Revenue, by Extremity (2017-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Component (2017-2030)
- 21.3. Market Revenue, by Type (2017-2030)
- 21.4. Market Revenue, by Extremity (2017-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Component (2017-2030)
- 22.3. Market Revenue, by Type (2017-2030)
- 22.4. Market Revenue, by Extremity (2017-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Component (2017-2030)
- 23.3. Market Revenue, by Type (2017-2030)
- 23.4. Market Revenue, by Extremity (2017-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Component (2017-2030)
- 24.3. Market Revenue, by Type (2017-2030)
- 24.4. Market Revenue, by Extremity (2017-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Component (2017-2030)
- 25.3. Market Revenue, by Type (2017-2030)
- 25.4. Market Revenue, by Extremity (2017-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Component (2017-2030)
- 26.3. Market Revenue, by Type (2017-2030)
- 26.4. Market Revenue, by Extremity (2017-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Component (2017-2030)
- 27.3. Market Revenue, by Type (2017-2030)
- 27.4. Market Revenue, by Extremity (2017-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Component (2017-2030)
- 28.3. Market Revenue, by Type (2017-2030)
- 28.4. Market Revenue, by Extremity (2017-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Ekso Bionics Holdings Inc.
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. ReWalk Robotics Ltd.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Parker-Hannifin Corporation
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. BIONIK Laboratories Corp.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Rex Bionics Ltd.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. B-Temia Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Bioventus LLC
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Hocoma AG
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
